Table 2.
Frequency of positive results of salivary and serum anti-Dsg 1 and anti-Dsg 3 ELISA in PV patients according to their disease phenotype.
| Disease phenotype | N (%) | Saliva ELISA | Serum ELISA | ||
|---|---|---|---|---|---|
| Anti-Dsg 1 (%) | Anti-Dsg 3 (%) | Anti-Dsg 1 (%) | Anti-Dsg 3 (%) | ||
| Mucosal | 19 (22.1%) | 2 (10.5%) | 12 (63.2%) | 6 (31.6%) | 17 (89.5%) |
| Cutaneous | 5 (5.8%) | 1 (20.0%) | 1 (20.0%) | 4 (80.0%) | 4 (80.0%) |
| Mucocutaneous | 62 (72.1%) | 28 (45.2%) | 50 (80.6%) | 52 (83.9%) | 62 (100.0%) |
|
| |||||
| Total | 86 (100.0%) | 31 (36.0%) | 63 (73.3%) | 62 (72.1%) | 83 (96.5%) |